Stifel Nicolaus Issues Pessimistic Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price objective decreased by equities researchers at Stifel Nicolaus from $72.00 to $60.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 46.59% from the stock’s current price.

A number of other research analysts have also weighed in on LIVN. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Mizuho decreased their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Finally, Needham & Company LLC decreased their price objective on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $64.20.

LivaNova Trading Down 1.3 %

Shares of NASDAQ:LIVN opened at $40.93 on Wednesday. LivaNova has a 1 year low of $40.37 and a 1 year high of $64.47. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 97.45 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The business’s 50 day moving average price is $47.52 and its 200-day moving average price is $49.50.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its stake in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after purchasing an additional 289 shares during the last quarter. Atria Investments Inc increased its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the last quarter. Finally, Xponance Inc. increased its position in shares of LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.